Oligometastatic Cancers and SBRT

This session delves into the biological rationale behind SBRT for oligometastatic disease, review emerging clinical evidence supporting its use, and discuss patient selection criteria. Participants gain insights into how SBRT fits within the broader treatment paradigm, including its integration with systemic therapies and immunotherapy. Additionally, the session addresses challenges such as toxicity management, optimal dose-fractionation schedules, and ongoing clinical trials that may further refine treatment strategies.

Target Audience

The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.

Learning Objectives

Upon completion of this activity, participants should be able to do the following:

  • Evaluate the rationale and clinical evidence supporting the use of SBRT in the management of oligometastatic cancers, including its potential impact on disease progression and patient survival.
  • Identify appropriate patient selection criteria for SBRT, understand its integration with systemic therapies, and recognize key considerations for optimizing treatment planning and toxicity management.
Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.
Course opens: 
04/21/2025
Course expires: 
04/20/2027
Cost:
$0.00
Part of: 
2025 ASTRO Annual Refresher Course onDemand
Rating: 
0

Faculty Disclosures

Planning Committee Disclosures
 

The person(s) above served as the developer(s) of this activity. Additionally, ASTRO Education Committee had control over the content of this activity.

All relevant relationships have been mitigated.

Disclosure link: 
ASTRO Education Committee

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Certificate of Attendance
    This activity was designated for 1.25 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.